Startseite Improving diagnosis of pneumococcal disease by multiparameter testing and micro/nanotechnologies
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Improving diagnosis of pneumococcal disease by multiparameter testing and micro/nanotechnologies

  • Georgette B. Salieb-Beugelaar

    Georgette B. Salieb-Beugelaar’s professional life started in the fields of clinical genetics, DNA research and diagnostics at the Academic Medical Centre in Amsterdam (The Netherlands) in 1996. She studied Chemistry at the University of Utrecht (The Netherlands) between 2000 and 2003. In 2005, her professional field changed into the microfluidic and nanofluidic world at the University of Twente in Enschede (The Netherlands) where she investigated single DNA molecules in nanoconfined environments on chips yielding in her PhD degree in 2009. The following 2 years she spent working at the Korean Institute of Science and Technology (Saarbrücken, Germany) on nanodropled pseudocrystals in microfluidic chips. Meanwhile, she was also working for the Mesa Institute for Nanotechnology (Twente University), during the set up of their BioNano Laboratory. Since November 2012, Georgette has become a member of the multidisciplinary NanoMedicine Group of Prof. Patrick Hunziker, working for the DiscoGnosis project (www.discognosis.eu) till January 2016 and is at present developing microfluidics for diagnostic purposes. Georgette is also currently involved in this journal as the scientific managing editor and active as managing editor of Progress in Materials Science (Elsevier).

     EMAIL logo     , Bei Zhang

    Bei Zhang received her Bachelor of Medicine (BMed) and Master of Medicine (MMed) in Clinical Laboratory Diagnostic Science at Shanghai Second Medical University, China. Since 1993 she worked as a microbiologist for more than 15 years in the Laboratory Diagnostic Center at Shanghai Children’s Medical Center affiliated to Shanghai JiaoTong University and was promoted to Associate Professor in 2005. She obtained her PhD in Medical and Biological Research from University of Basel, Switzerland in 2012. After that, she joined the Nanomedicine Research Lab CLINAM, Medical Intensive Care Unit (MedInt), University Hospital Basel as a postdoc working for European Commission (EC)-funded DiscoGnosis project. She has published more than 30 papers in peer-reviewed journals.

         , Maurice M. Nigo

    Maurice M. Nigo began his professional life in the fields of microbiology and epidemiology of communicable diseases at the Department of Pathology of the University of Liege (Belgium) in 1993. Since 1996, he has been giving lectures on Medical Microbiology and Medical Parasitology at the “Institut Supérieur des Techniques Médicales de Nyankunde” at Bunia (DR Congo). In 2004, he was the Principal Investigator of the Survey for the Validation of the Rapid Assessment Procedure for Loiasis (RAPLOA) in the north-eastern area of the Democratic Republic of Congo. Between 2008 and 2012, he was the Head of Laboratory of the “Centre de Recherche en Maladies Tropicales de l’Ituri” for the WHO/TDR and Wieth/Pfizer Phase III Moxidectin Trial at Rethy (DR Congo). Since November 2014, Maurice has been a member of the multidisciplinary NanoMedicine Group of Prof. Patrick Hunziker, and he worked for the DiscoGnosis project (www.discognosis.eu). Now Maurice is a PhD student working on blood fluke diagnosis and epidemiology.

         , Sieghard Frischmann

    Sieghard Frischmann is head of R&D and production at Mast. He is leading a team of scientists for the development of molecular diagnostic assays based on the LAMP technology. As a regulatory board member at Mast he works as a medical product safety manager according to the German Medical Product Law. Sieghard Frischmann joined Mast Diagnostica GmbH in 1992.

         und Patrick R. Hunziker

    Patrick R. Hunziker studied Medicine at the University of Zurich, Switzerland. He received a doctoral degree based on thesis work in experimental immunology from the University of Zurich and did further research in experimental hematology at the University Hospital in Zurich, Switzerland. He earned specialist degrees in Internal Medicine, Cardiology and Intensive Care Medicine. As a fellow of the Massachusetts General Hospital, Harvard Medical School, he worked on cardiac imaging in a joint project with the Massachusetts Institute of Technology, Cambridge. His professional activities in Europe, the US, Africa and China have given him a broad insight into the needs for the medicine of the future in a variety of settings. Patrick R. Hunziker became involved in the medical applications of nanoscience in the late 1990s and has been the pioneering physician in nanomedicine in Switzerland since then. With improved prevention, diagnosis and the cure for cardiovascular disease as his main research topics, he has worked in the nanoscience fields of atomic force microscopy, nano-optics, micro/nanofluidics, nanomechanical sensors and polymer nanocarriers for targeting. He is the founding president of the European Society of Nanomedicine, cofounder of the European Foundation for Clinical Nanomedicine and coinitiator of the European Conference for Clinical Nanomedicine and is clinically active as deputy head of the Clinic for Intensive Care Medicine at the University Hospital Basel, Switzerland. In November 2008 Patrick R. Hunziker became professor for Cardiology and Intensive Care Medicine at the University of Basel.
Veröffentlicht/Copyright: 3. Juni 2016
Veröffentlichen auch Sie bei De Gruyter Brill
Informationen für Autor*innen
European Journal of Nanomedicine
Aus der Zeitschrift European Journal of Nanomedicine Band 8 Heft 3

Abstract

The diagnosis and management of pneumococcal disease remains challenging, in particular in children who often are asymptomatic carriers, and in low-income countries with a high morbidity and mortality from febrile illnesses where the broad range of bacterial, viral and parasitic cases are in contrast to limited, diagnostic resources. Integration of multiple markers into a single, rapid test is desirable in such situations. Likewise, the development of multiparameter tests for relevant arrays of pathogens is important to avoid overtreatment of febrile syndromes with antibiotics. Miniaturization of tests through use of micro- and nanotechnologies combines several advantages: miniaturization reduces sample requirements, reduces the use of consumables and reagents leading to a reduction in costs, facilitates parallelization, enables point-of-care use of diagnostic equipment and even reduces the amount of potentially infectious disposables, characteristics that are highly desirable in most healthcare settings. This critical review emphasizes our vision on the importance of multiparametric testing for diagnosing pneumococcal infections in patients with fever and examines recent relevant developments in micro/nanotechnologies to achieve this goal.

Keywords: immunoassays; microfluidics; nanodiagnostics; nanotechnology; pneumococcal disease; point-of-care; rapid tests

About the authors

Georgette B. Salieb-Beugelaar

Georgette B. Salieb-Beugelaar’s professional life started in the fields of clinical genetics, DNA research and diagnostics at the Academic Medical Centre in Amsterdam (The Netherlands) in 1996. She studied Chemistry at the University of Utrecht (The Netherlands) between 2000 and 2003. In 2005, her professional field changed into the microfluidic and nanofluidic world at the University of Twente in Enschede (The Netherlands) where she investigated single DNA molecules in nanoconfined environments on chips yielding in her PhD degree in 2009. The following 2 years she spent working at the Korean Institute of Science and Technology (Saarbrücken, Germany) on nanodropled pseudocrystals in microfluidic chips. Meanwhile, she was also working for the Mesa Institute for Nanotechnology (Twente University), during the set up of their BioNano Laboratory. Since November 2012, Georgette has become a member of the multidisciplinary NanoMedicine Group of Prof. Patrick Hunziker, working for the DiscoGnosis project (www.discognosis.eu) till January 2016 and is at present developing microfluidics for diagnostic purposes. Georgette is also currently involved in this journal as the scientific managing editor and active as managing editor of Progress in Materials Science (Elsevier).

Bei Zhang

Bei Zhang received her Bachelor of Medicine (BMed) and Master of Medicine (MMed) in Clinical Laboratory Diagnostic Science at Shanghai Second Medical University, China. Since 1993 she worked as a microbiologist for more than 15 years in the Laboratory Diagnostic Center at Shanghai Children’s Medical Center affiliated to Shanghai JiaoTong University and was promoted to Associate Professor in 2005. She obtained her PhD in Medical and Biological Research from University of Basel, Switzerland in 2012. After that, she joined the Nanomedicine Research Lab CLINAM, Medical Intensive Care Unit (MedInt), University Hospital Basel as a postdoc working for European Commission (EC)-funded DiscoGnosis project. She has published more than 30 papers in peer-reviewed journals.

Maurice M. Nigo

Maurice M. Nigo began his professional life in the fields of microbiology and epidemiology of communicable diseases at the Department of Pathology of the University of Liege (Belgium) in 1993. Since 1996, he has been giving lectures on Medical Microbiology and Medical Parasitology at the “Institut Supérieur des Techniques Médicales de Nyankunde” at Bunia (DR Congo). In 2004, he was the Principal Investigator of the Survey for the Validation of the Rapid Assessment Procedure for Loiasis (RAPLOA) in the north-eastern area of the Democratic Republic of Congo. Between 2008 and 2012, he was the Head of Laboratory of the “Centre de Recherche en Maladies Tropicales de l’Ituri” for the WHO/TDR and Wieth/Pfizer Phase III Moxidectin Trial at Rethy (DR Congo). Since November 2014, Maurice has been a member of the multidisciplinary NanoMedicine Group of Prof. Patrick Hunziker, and he worked for the DiscoGnosis project (www.discognosis.eu). Now Maurice is a PhD student working on blood fluke diagnosis and epidemiology.

Sieghard Frischmann

Sieghard Frischmann is head of R&D and production at Mast. He is leading a team of scientists for the development of molecular diagnostic assays based on the LAMP technology. As a regulatory board member at Mast he works as a medical product safety manager according to the German Medical Product Law. Sieghard Frischmann joined Mast Diagnostica GmbH in 1992.

Patrick R. Hunziker

Patrick R. Hunziker studied Medicine at the University of Zurich, Switzerland. He received a doctoral degree based on thesis work in experimental immunology from the University of Zurich and did further research in experimental hematology at the University Hospital in Zurich, Switzerland. He earned specialist degrees in Internal Medicine, Cardiology and Intensive Care Medicine. As a fellow of the Massachusetts General Hospital, Harvard Medical School, he worked on cardiac imaging in a joint project with the Massachusetts Institute of Technology, Cambridge. His professional activities in Europe, the US, Africa and China have given him a broad insight into the needs for the medicine of the future in a variety of settings. Patrick R. Hunziker became involved in the medical applications of nanoscience in the late 1990s and has been the pioneering physician in nanomedicine in Switzerland since then. With improved prevention, diagnosis and the cure for cardiovascular disease as his main research topics, he has worked in the nanoscience fields of atomic force microscopy, nano-optics, micro/nanofluidics, nanomechanical sensors and polymer nanocarriers for targeting. He is the founding president of the European Society of Nanomedicine, cofounder of the European Foundation for Clinical Nanomedicine and coinitiator of the European Conference for Clinical Nanomedicine and is clinically active as deputy head of the Clinic for Intensive Care Medicine at the University Hospital Basel, Switzerland. In November 2008 Patrick R. Hunziker became professor for Cardiology and Intensive Care Medicine at the University of Basel.

Acknowledgments:

We thank Prof. Rutledge Ellis-Behnke of the Medical Faculty Mannheim of the University of Heidelberg (Germany) for the support in knowledge. This review has been written to contribute to the DiscoGnosis project that has the core objective to develop a platform that would allow the detection of malaria and similar pathogenic diseases in a rapid, multiplexed and non-invasive. The project is supported by the European Commission through the 7th Framework Programme on Research and Technological Development within the Objective FP7 ICT- 2011.3.2 and under Grant Agreement [No. 318408].

  1. Conflict of interest statement: Authors state no conflict of interest. All authors have read the Journal’s publication ethics and publication malpractice statement available at the journal’s website and hereby confirm that they comply with all its parts applicable to the present scientific work.

References

1. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations and antibiotic resistance. J Korean Med Sci 2013;28:4–15.10.3346/jkms.2013.28.1.4Suche in Google Scholar

2. Huang SS, Finkelstein JA, Rifas-Shiman SL, Kleinman K, Platt R. Community-level predictors of pneumococcal carriage and resistance in young children. Am J Epidemiol 2004;159:645–54.10.1093/aje/kwh088Suche in Google Scholar

3. “Streptococcus Pneumoniae. Textbook in Diagnosis, Serotyping, Virulence Factors and Enzyme-linked Immunosorbent Assay (ELISA) for Measuring Pneumococcal Antibodies.” (2nd version; 2015) Statens Serum Institut, Denmark.Suche in Google Scholar

4. Skov Sørensen UB, Blom J, Birch-Andersen A, Henrichsen J. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect Immun 1988;56:1890–6.10.1128/iai.56.8.1890-1896.1988Suche in Google Scholar

5. Gilbert RJ, Jiménez JL, Chen S, Tickle IJ, Rossjohn J, Parker M, et al. Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell 1999;97:647–55.10.1016/S0092-8674(00)80775-8Suche in Google Scholar

6. Ren, B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 2003;71:75–85.10.1128/IAI.71.1.75-85.2003Suche in Google Scholar

7. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 1999;67:4720–4.10.1128/IAI.67.9.4720-4724.1999Suche in Google Scholar

8. Dave S, Brooks-Walter A, Pangburn MK, McDaniel LS. PspC, a pneumococcal surface protein, binds human factor H. Infect Immun 2001;69:3435–7.10.1128/IAI.69.5.3435-3437.2001Suche in Google Scholar

9. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Bjorck L, Meri S. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8–11 of factor H. J Immunol 2002;168:1886–94.10.4049/jimmunol.168.4.1886Suche in Google Scholar

10. Dintilhac A, Alloing G, Granadel C, Claverys JP. Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol 1997;25:727–39.10.1046/j.1365-2958.1997.5111879.xSuche in Google Scholar

11. Mosser JL, Tomasz A. Choline-containing teichoic acid as a structural com- ponent of pneumococcal cell wall and its role in sensitivity to lysis by an autolytic enzyme. J Biol Chem 1970;245:287–98.10.1016/S0021-9258(18)63393-9Suche in Google Scholar

12. Berry AM, Lock RA, Paton JC. Cloning and characterization of NanB, a second Streptococcus pneumoniae neuraminidase gene, and purification of the NanB enzyme from recombinant Escherichia coli. J Bacteriol 1996;178:4854–60.10.1128/jb.178.16.4854-4860.1996Suche in Google Scholar PubMed PubMed Central

13. Janoff EN, Rubins JB, Fasching C, Charboneau D, Rahkola JT, Plaut AG, et al. Pneumococcal IgA1 protease subverts specific protection by human IgA1. Mucosal Immunol 2014;7:249–56.10.1038/mi.2013.41Suche in Google Scholar PubMed PubMed Central

14. Calix JJ, Dagan R, Pelton SI, Porat N, Nahm MH. Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution. Clin Infect Dis 2012;54:794–9.10.1093/cid/cir953Suche in Google Scholar PubMed PubMed Central

15. Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010;50:329–37.10.1086/649872Suche in Google Scholar PubMed

16. Mukabatsinda C, Nguyen J, Bisig B, Lynen L, Coppens YD, Asiimwe A, et al. Is increasing complexity of algorithms the price for higher accuracy? Virtual comparison of three algorithms for tertiary level management of chronic cough in people living with HIV in a low-income country. BMC Med Inform Decis Mak 2012;12:2.10.1186/1472-6947-12-2Suche in Google Scholar PubMed PubMed Central

17. Song JY, Eun BW, Nahm MH. Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. Infect Chemother 2013;45:351–366.10.3947/ic.2013.45.4.351Suche in Google Scholar PubMed PubMed Central

18. Werno AM, Murdoch DR. Medical microbiology: laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis 2008;46:926–32.10.1086/528798Suche in Google Scholar PubMed

19. Kellogg JA, Bankert DA, Elder CJ, Gibbs JL, Smith MC. Identification of Streptococcus pneumoniae revisited. J Clin Microbiol 2001;39:3373–5.10.1128/JCM.39.9.3373-3375.2001Suche in Google Scholar PubMed PubMed Central

20. Greve T, Møller JK. Accuracy of using the lytA gene to distinguish Streptococcus pneumoniae from related species. J Med Microbiol 2012;61:478–82.10.1099/jmm.0.036574-0Suche in Google Scholar PubMed

21. Brown S, Santa Maria JP Jr, Walker S. Wall teichoic acids of gram-positive bacteria. Annu Rev Microbiol 2013;67:313–36.10.1146/annurev-micro-092412-155620Suche in Google Scholar PubMed PubMed Central

22. Sinclair A, Xie X, Teltscher M, Dendukuri N. Systematic re-view and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneu-monia caused by Streptococcus pneumoniae. J Clin Microbiol 2013;51:2303–10.10.1128/JCM.00137-13Suche in Google Scholar PubMed PubMed Central

23. Frasch CE, Conception NF. Specificity of human antibodies reactive with pneumococcal C polysaccharide. Infect Immun 2000;68:2333–7.10.1128/IAI.68.4.2333-2337.2000Suche in Google Scholar PubMed PubMed Central

24. Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol 2012;19:1131–41.10.1128/CVI.00064-12Suche in Google Scholar PubMed PubMed Central

25. Pickering JW, Hill HR. Measurement of Antibodies to Pneumococcal Polysaccharides with Luminex xMAP Microsphere-Based Liquid Arrays. Methods Mol Biol 2011;808:361–375.10.1007/978-1-61779-373-8_24Suche in Google Scholar PubMed

26. Ortika BD, Habib M, Dunne EM, Porter BD, Satzke C. Production of latex agglutination reagents for pneumococcal serotyping. BMC Res Notes 2013;6:49.10.1186/1756-0500-6-49Suche in Google Scholar PubMed PubMed Central

27. File TM, Kozlov RS. Rapid detection of Streptococcus pneumoniae in community-acquired pneumonia. Clin Microbiol Infect 2006;12(Suppl 9):27–33.10.1111/j.1469-0691.2006.01653.xSuche in Google Scholar

28. del Mar García-Suárez M, Cima-Cabal MD, Villaverde R, Espinosa E, Falguera M, de Los Toyos JR, et al. Performance of a pneumolysin enzyme-linked immunosorbent assay for diagnosis of pneumococcal infections. J Clin Microbiol 2007;45:3549–54.10.1128/JCM.01030-07Suche in Google Scholar PubMed PubMed Central

29. Moïsi JC, Saha SK, Falade AG, Njanpop-Lafourcade BM, Oundo J, Zaidi AKM, et al. Enhanced diagnosis of pneumococcal meningitis using the Binax NOW® S. pneumoniae immuno-chromatographic test: a multi-site study. Clin Infect Dis 2009;48(Suppl 2):S49–56.10.1086/596481Suche in Google Scholar PubMed PubMed Central

30. Jado I, Fenoll A, Casal J, Pérez A. Identification of the psaA gene, coding for pneumococcal surface adhesin A, in viridans group streptococci other than Streptococcus pneumoniae. Clin Diagn Lab Immunol 2001;8:895–8.10.1128/CDLI.8.5.895-898.2001Suche in Google Scholar PubMed PubMed Central

31. Janulczyk R, Iannelli F, Sjoholm AG, Pozzi G, Bjorck L. Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem 2000;275:37257–63.10.1074/jbc.M004572200Suche in Google Scholar PubMed

32. Ye W, Hu Y, Zhang R, Ying K. Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in lower respiratory tract infections: a meta-analysis. Respirology 2014;19:501–7.10.1111/resp.12270Suche in Google Scholar PubMed

33. Huang H, Ideh RC, Gitau E, Thézénas ML, Jallow M, Ebruke B, et al. Discovery and validation of biomarkers to guide clinical management of pneumonia in African children. Clin Infect Dis 2014;58:1707–15.10.1093/cid/ciu202Suche in Google Scholar PubMed PubMed Central

34. Murdoch DR, Anderson TP, Beynon KA, Chua A, Fleming AM, Laing RT, et al. Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-acquired pneumonia. J Clin Microbiol 2003;41:63–6.10.1128/JCM.41.1.63-66.2003Suche in Google Scholar PubMed PubMed Central

35. Dhoubhadel BG, Yasunami M, Yoshida LM, Thi HA, Thi TH, Thi TA, et al. A novel high-throughput method for molecular serotyping and serotype-specific quantification of Streptococcus pneumoniae using a nanofluidic real-time PCR system. J Med Microbiol 2014;63(Pt 4):528–39.10.1099/jmm.0.071464-0Suche in Google Scholar PubMed

36. Messaoudi M, Milenkov M, Albrich WC, van der Linden MP, Bénet T, Chou M, et al. The relevance of a novel quantitative assay to detect up to 40 major streptococcus pneumoniae serotypes directly in clinical nasopharyngeal and blood specimens. PLoS One 2016;11:e0151428.10.1371/journal.pone.0151428Suche in Google Scholar PubMed PubMed Central

37. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 2006;44:124–31.10.1128/JCM.44.1.124-131.2006Suche in Google Scholar PubMed PubMed Central

38. Habets MN, Cremers AJ, Bos MP, Savelkoul P, Eleveld MJ, Meis JF et al. A novel quantitative PCR assay for the detection of Streptococcus pneumoniae using the competence regulator gene target comX. J Med Microbiol 2016;65:129–36.10.1099/jmm.0.000204Suche in Google Scholar PubMed

39. Linder A, Hollingshead S, Janulczyk R, Christensson B, Akesson P. Human antibody response towards the pneumococcal surface proteins PspA and PspC during invasive pneumococcal infection. Vaccine 2007;25:341–5.10.1016/j.vaccine.2006.07.028Suche in Google Scholar PubMed

40. Kolberg J, Aase A, Næss LM, Aaberge IS, Caugant DA. Human antibody responses to pneumococcal surface protein A and capsular polysaccharides during acute and convalescent stages of invasive disease in adult patients. Pathog Dis 2014;70:40–50.10.1111/2049-632X.12106Suche in Google Scholar PubMed

41. Andrade DC, Borges IC, Laitinen H, Ekström N, Adrian PV, Meinke A, et al. A fluorescent multiplexed bead-based immunoassay (FMIA) for quantitation of IgG against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis protein antigens. J Immunol Methods 2014;405:130–43.10.1016/j.jim.2014.02.002Suche in Google Scholar PubMed

42. Larsson MC, Karlsson E, Woksepp H, Frölander K, Mårtensson A, Rashed F, et al. Rapid identification of pneumococci, enterococci, beta-haemolytic streptococci and S. aureus from positive blood cultures enabling early reports. BMC Infect Dis 2014;14:146.10.1186/1471-2334-14-146Suche in Google Scholar PubMed PubMed Central

43. Cremers AJ, Hagen F, Hermans PW, Meis JF, Ferwerda G. Diagnostic value of serum pneumococcal DNA load during invasive pneumococcal infections. Eur J Clin Microbiol Infect Dis 2014;33:1119–24.10.1007/s10096-014-2050-xSuche in Google Scholar PubMed

44. Chen M, Zhou M, Xiao W, Ai B, Liu X, Li Y. The urinary antigen tests have high sensitivity in diagnosis of pneumococcus caused community-acquired pneumonia posterior to antimicrobial therapy. Cell Biochem Biophys 2014;70:1029–34.10.1007/s12013-014-0015-4Suche in Google Scholar PubMed

45. Fall B, Lo CI, Samb-Ba B, Perrot N, Diawara S, Gueye MW, et al. The ongoing revolution of MALDI-TOF mass spectrometry for microbiology reaches tropical africa. Am J Trop Med Hyg 2015;92:641–7.10.4269/ajtmh.14-0406Suche in Google Scholar PubMed PubMed Central

46. Galetto-Lacour A, Alcoba G, Posfay-Barbe KM, Cevey-Macherel M, Gehri M, Ochs MM, et al. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal community-acquired pneumonia in children. Pediatr Infect Dis J 2013;32:1175–9.10.1097/INF.0b013e31829ba62aSuche in Google Scholar PubMed

47. Strachan RE, Cornelius A, Gilbert GL, Gulliver T, Martin A, McDonald T, et al. A bedside assay to detect streptococcus pneumoniae in children with empyema. Pediatr Pulmonol 2011;46:179–83.10.1002/ppul.21349Suche in Google Scholar PubMed

48. Picazo JJ, Contreras JR, Ríos E, Culebras E, Rodríguez-Avi-al I, Méndez C, et al. Rapid diagnosis of invasive pneumococcal disease in pediatric population. J Microbiol Methods 2013;93:116–20.10.1016/j.mimet.2013.03.001Suche in Google Scholar PubMed

49. Martinón-Torres F, Dosil-Gallardo S, Perez del Molino-Bernal ML, Sánchez FP, Tarrago D, Alvez F, et al. Pleural antigen assay in the diagnosis of pediatric pneumococcal empyema. J Crit Care 2012;27:321.e1–4.10.1016/j.jcrc.2011.05.004Suche in Google Scholar PubMed

50. Lee JH, Kim SH, Lee J, Choi EH, Lee HJ. Diagnosis of pneumococcal empyema using immunochromatographic test on pleural fluid and serotype distribution in Korean children. Diagn Microbiol Infect Dis 2012;72:119–124.10.1016/j.diagmicrobio.2011.09.025Suche in Google Scholar PubMed

51. Salieb-Beugelaar GB, Hunziker PR. Towards nano- diagnostics for bacterial infections. Eur J Nanomed 2015;7:37–50.10.1515/ejnm-2015-0010Suche in Google Scholar

52. Salieb-Beugelaar GB, Hunziker PR. Towards nano-diagnostics for rapid diagnosis of infectious diseases-current technological state. Eur J Nanomed 2014;6:11–28.10.1515/ejnm-2014-0004Suche in Google Scholar

53. Park S, Zhang Y, Wang TH, Yang S. Continuous dielectrophoretic bacterial separation and concentration from physiological media of high conductivity. Lab Chip 2011;11:2893–900.10.1039/c1lc20307jSuche in Google Scholar PubMed

54. Ai Y, Sanders CK, Marrone BL. Separation of Escherichia coli bacteria from peripheral blood mononuclear cells using standing surface acoustic waves. Anal Chem 2013;85:9126–34.10.1021/ac4017715Suche in Google Scholar PubMed PubMed Central

55. Ranjan S, Zeming KK, Jureen R, Fisher D, Zhang Y. Dld pillar shape design for efficient separation of spherical and non-sherical bioparticles. Lab Chip 2014;14:4250–62.10.1039/C4LC00578CSuche in Google Scholar

56. Kang DK, Ali MM, Zhang K, Huang SS, Peterson E, Digman MA et al. Rapid detection of single bacteria in unprocessed blood using integrated comprehensive droplet digital detection. Nat Commun 2014;5:5427.10.1038/ncomms6427Suche in Google Scholar PubMed PubMed Central

57. Sajid M, Kawde AN, Daus M. Designs, formats and applications of lateral flow assay: a literature review. J Saudi Chem Soc 2015;19:689–705.10.1016/j.jscs.2014.09.001Suche in Google Scholar

58. Shen J, Li Y, Gu H, Xia F, Zuo X. Recent development of sandwich assay based on the nanobiotechnologies for proteins, nucleic acids, small molecules, and ions. Chem Rev 2014;114:7631–77.10.1021/cr300248xSuche in Google Scholar PubMed

59. Pedrosa P, Baptista PV. Gold and silver nanoparticles for diagnostics of infection. Nanotechnology in diagnosis, treatment and prophylaxis of infectious diseases, 2015. Edited by: Mahendra Rai and Kateryna Kon ISBN: 978-0-12-801317-5.Suche in Google Scholar

60. Wu TY, Su YY, Shu WH, Mercado AT, Wang SK, Hsu LY, et al. A novel sensitive pathogen detection system based on microbead quantum dot system. Biosens Bioelectron 2016;78:37–44.10.1016/j.bios.2015.11.016Suche in Google Scholar PubMed

61. Brenner S, Johnson M, Bridgham J, Golda G, Lloyd DH, Johnson D, et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat. Biotechnol. 2000;18:630–4.10.1038/76469Suche in Google Scholar PubMed

62. Veigas B, Pedrosa P, Carlos FF, Mancio-Silva L, Grosso AR, Fortunato E. One nanoprobe, two pathogens: gold nanoprobes multiplexing for point-of-care. J Nanobiotechnol 2015;13:48.10.1186/s12951-015-0109-1Suche in Google Scholar PubMed PubMed Central

63. Veigas B, Jacob JM, Costa MN, Santos DS, Viveiros M, Inacio J, et al. Gold on paper–paper platform for Au-nanoprobe TB detection. Lab Chip 2012;12:4802–8.10.1039/c2lc40739fSuche in Google Scholar PubMed

64. Luo J, Fang X, Ye D, Li H, Chen H, Zhang S, et al. A real-time microfluidic multiplex electrochemical loop-mediated isothermal amplification chip for differentiating bacteria. Biosens Bioelectron 2014;60:84–91.10.1016/j.bios.2014.03.073Suche in Google Scholar PubMed

65. Ju HX, Zhou J, Cai CX, Chen HY. The electrochemical behavior of methylene blue at a microcylinder carbon fiber electrode. Electroanalysis 1995;7:1165–70.10.1002/elan.1140071213Suche in Google Scholar

66. Kotanen CN, Martinez L, Alvarez R, Simecek JW. Surface enhanced Raman scattering spectroscopy for detection and identification of microbial pathogens isolated from human serum. Sens Bio sensing Res 2016;8:20–6.10.1016/j.sbsr.2016.03.002Suche in Google Scholar

67. Walter A, März A, Schumacher W, Rösch P, Popp J. Towards a fast, high specific and reliable discrimination of bacteria on strain level by means of SERS in a microfluidic device. Lab Chip 2011;11:1013.10.1039/c0lc00536cSuche in Google Scholar PubMed

68. Pahlow S, Meisel S, Cialla-May D, Weber K, Rösch P, Popp J. Isolation and identification of bacteria by means of Raman spectroscopy. Adv Drug Del Rev 2015;89:105–20.10.1016/j.addr.2015.04.006Suche in Google Scholar PubMed

69. Bouguelia S, Roupioz Y, Slimani S, Mondani L, Casabona MG, Durmort C, et al. On-chip microbial culture for the specific detection of very low levels of bacteria. Lab Chip 2013;13: 4024–32.10.1039/c3lc50473eSuche in Google Scholar PubMed

70. Abadian PN, Kelley CP, Goluch ED. Cellular analysis and detection using surface plasmon resonance techniques. Anal Chem 2014;86:2799–812.10.1021/ac500135sSuche in Google Scholar PubMed

71. Schmid D, Lang H, Marsch S, Gerber C, Hunziker P. Diagnosing disease by nanomechanical olfactory sensors – system design and clinical validation. Eur J Nanomed 2008;1:44–7.10.1515/EJNM.2008.1.1.44Suche in Google Scholar

72. Lang HP, Ramseyer JP, Grange W, Braun T, Schmid D, Hunziker P, et al. An artificial nose based on microcantilever array sensors. J Phys Conf Ser 2007;61:663.10.1088/1742-6596/61/1/133Suche in Google Scholar

73. Tang KT, Chiu SW, Shih CH, Chang CL, Yang CM, Yao DJ, et al. 24.5 A 0.5V 1.27mW nose-on-a-chip for rapid diagnosis of ventilator-associated pneumonia (Conference Paper). IEEE International Solid-State Circ Conf 2014;57:420–21.10.1109/ISSCC.2014.6757496Suche in Google Scholar

Received: 2016-4-25
Accepted: 2016-5-12
Published Online: 2016-6-3
Published in Print: 2016-7-1

©2016 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. In this issue
  3. News
  4. CLINAM 2016 summit June 26–29, 2016
  5. Special section Nanotechnology for infectious diseases
  6. Editorial
  7. Nanomedicine translation from enabling technologies to the patient: focus on infectious diseases
  8. Critical Review
  9. Improving diagnosis of pneumococcal disease by multiparameter testing and micro/nanotechnologies
  10. Original Articles
  11. Solid lipid nanoparticles encapsulating a fluorescent marker (coumarin 6) and antimalarials – artemether and lumefantrine: evaluation of cellular uptake and antimalarial activity
  12. Nano-mupirocin: enabling the parenteral activity of mupirocin
  13. Regular contributions
  14. Review
  15. Radio-nanomaterials for biomedical applications: state of the art
https://doi.org/10.1515/ejnm-2016-0012
Schlagwörter für diesen Artikel
immunoassays; microfluidics; nanodiagnostics; nanotechnology; pneumococcal disease; point-of-care; rapid tests

Artikel in diesem Heft

  1. Frontmatter
  2. In this issue
  3. News
  4. CLINAM 2016 summit June 26–29, 2016
  5. Special section Nanotechnology for infectious diseases
  6. Editorial
  7. Nanomedicine translation from enabling technologies to the patient: focus on infectious diseases
  8. Critical Review
  9. Improving diagnosis of pneumococcal disease by multiparameter testing and micro/nanotechnologies
  10. Original Articles
  11. Solid lipid nanoparticles encapsulating a fluorescent marker (coumarin 6) and antimalarials – artemether and lumefantrine: evaluation of cellular uptake and antimalarial activity
  12. Nano-mupirocin: enabling the parenteral activity of mupirocin
  13. Regular contributions
  14. Review
  15. Radio-nanomaterials for biomedical applications: state of the art
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 9.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ejnm-2016-0012/html
Button zum nach oben scrollen